Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
Castle Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected three Class I directors — Ellen Goldberg, Miles D. Harrison and Tiffany P. Olson — each to serve until the 2029 annual meeting, with support ranging from 14.4 million to 15.6 million votes in favor and 2.4 million broker non-votes. They also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 24.5 million votes for and minimal opposition. In advisory and related votes, stockholders approved the compensation of the company’s named executive officers, with about 21.3 million votes in favor versus 1.3 million against, and approved the non-employee director compensation policy by similar margins.
Castle Biosciences Inc. director Cole G. Bradley reported a compensation-related stock transaction. Bradley exercised previously granted Restricted Stock Units (RSUs), receiving 13,667 shares of Common Stock at a stated price of $0.00 per share. Following this exercise, Bradley directly holds 32,976 shares of Common Stock. Each RSU represents the right to receive one share of Common Stock, with vesting tied to the earlier of a one-year anniversary of the grant date or the day before the next Annual Meeting of Stockholders.
Castle Biosciences director Daniel Bradbury reported routine equity compensation activity. He exercised 13,667 Restricted Stock Units, receiving the same number of shares of Common Stock at a stated price of $0.00 per share.
Following the transactions, he now holds 22,340 shares of Common Stock directly and 13,291 shares indirectly through the Bradbury Family Trust, where he and Annette Bradbury serve as trustees and beneficiaries.
Castle Biosciences director Miles Harrison exercised Restricted Stock Units into common stock. On May 22, 2026, 13,667 RSUs converted into 13,667 shares of Common Stock at no cash cost, leaving him with 35,631 common shares held directly after the transaction.
CASTLE BIOSCIENCES director Tiffany Olson exercised previously granted equity awards rather than trading shares on the market. On May 22, 2026, she converted 13,667 Restricted Stock Units (RSUs) into the same number of Common Stock shares at a price of $0.00 per share, reflecting compensation rather than a cash investment.
Following this RSU settlement, Olson directly holds 39,573 shares of Castle Biosciences Common Stock. The filing shows no open-market purchases or sales and no shares withheld for taxes, indicating a straightforward vesting and settlement of RSUs, each of which represents the right to receive one share of Common Stock.
Castle Biosciences director Ellen Goldberg exercised restricted stock units into common shares. On May 22, 2026, she converted 13,667 Restricted Stock Units into 13,667 shares of Common Stock at a stated price of $0.00 per share. Following this equity award conversion, she directly holds 40,921 shares of Castle Biosciences common stock. The filing shows no open-market purchases or sales, indicating a routine compensation-related share issuance rather than a discretionary trade.
Castle Biosciences director Kim Caple exercised equity awards into common stock. On May 22, 2026, Caple converted 13,667 Restricted Stock Units into 13,667 shares of Common Stock at a price of $0.00 per share, classified as a derivative exercise rather than a market purchase.
Following this transaction, Caple directly holds 36,121 shares of Common Stock. The filing shows no open-market sales or gifts, indicating a routine compensation-related equity settlement rather than a discretionary trade. Each RSU represented the right to receive one share of Common Stock.
CASTLE BIOSCIENCES INC director Rodney Cotton acquired shares through an equity award conversion. On May 22, 2026, he exercised Restricted Stock Units into 13,667 shares of Common Stock at a stated price of $0.00 per share.
Following this transaction, Cotton directly owned 32,998 shares of Common Stock. A corresponding derivative entry shows the 13,667 Restricted Stock Units converted into the same number of Common shares, leaving no RSUs from this grant outstanding.
CASTLE BIOSCIENCES INC Chief Commercial Officer Juvenal W. Tobin exercised stock options and increased his direct common share holdings. On 2026-05-21, he exercised options for 11,210 shares of common stock at an exercise price of $3.38 per share. Following this transaction, he directly holds 98,035 shares of common stock. The exercised option, which was fully vested, now has no remaining balance.
CASTLE BIOSCIENCES INC President and CEO Derek J. Maetzold reported a series of insider trades in May 2026 involving company common stock. Across several family trusts and a personal account, entities associated with him sold a net 4,172 shares in open-market transactions at prices around $20 per share.
On the same dates, he exercised stock options to acquire 550 shares at an exercise price of $2.39 per share, increasing his direct common stock holdings. Following these transactions, one direct holding account shows 21,479 shares, while certain family trusts continue to hold tens of thousands of shares. The filing notes that these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.